Standardized Measurement of Nasal Membrane Transepithelial Potential Difference (NPD)
September 13th, 2018
Here, we present a standardized protocol to measure the nasal potential difference (NPD). Cystic fibrosis transmembrane conductance regulator (CFTR) and epithelial sodium channel (ENaC) function are evaluated by the change in the voltage across the nasal epithelium after superfusion of solutions that modify ion channel activity, providing an outcome measure.
This method can help answer key questions in the CF and ion transport fields about whether CF patients can mount a meaningful response to activation or restoration of CFTR function.The main advantage of this technique is that it measures the coordinated activity of the CFTR and epithelial sodium channel in the airway epithelium.Although this method can provide insight into cystic fibrosis, it can also be applied to other disease systems, such as genetic disorders of hyperactive epithelial sodium channel function.Demonstrating the procedure will be Thao Nguyen, biologist, and Aur
Overview
This article presents a standardized protocol for measuring nasal potential difference (NPD), which evaluates the function of CFTR and ENaC channels. The method assesses changes in voltage across the nasal epithelium in response to specific solutions, providing insights into ion channel activity.
Key Study Components
Area of Science
- Cystic fibrosis research
- Ion transport mechanisms
- Respiratory physiology
Background
- The nasal potential difference (NPD) is a key measure in assessing CFTR function.
- Understanding ion transport is crucial for developing therapies for cystic fibrosis.
- This method can also be applied to other conditions involving epithelial sodium channel dysfunction.
- Previous studies have shown variable responses in CF patients to CFTR modulation.
Purpose of Study
- To provide a reliable protocol for measuring NPD in research settings.
- To evaluate the coordinated activity of CFTR and ENaC in airway epithelium.
- To explore the potential of this method in other disease systems.
Methods Used
- Superfusion of solutions that modify ion channel activity.
- Measurement of voltage changes across the nasal epithelium.
- Standardization of the NPD measurement protocol.
- Evaluation of patient responses to CFTR activation.
Main Results
- The method effectively measures the function of CFTR and ENaC.
- It provides insights into the ion transport capabilities of CF patients.
- Results indicate variability in responses to CFTR activation.
- The technique shows promise for application in other genetic disorders.
Conclusions
- This standardized protocol is a valuable tool for CF research.
- It enhances understanding of ion transport in cystic fibrosis.
- The method's applicability to other diseases could broaden its impact.
Frequently Asked Questions
Executive Industry Relevance
Standardized nasal potential difference (NPD) measurement provides a direct, quantitative assessment of CFTR and ENaC function in the airway epithelium, addressing a critical need for mechanistic de-risking in cystic fibrosis (CF) drug development. This electrophysiological readout enables predictive confidence in target engagement and functional restoration, supporting go/no-go decisions in early clinical and translational pipelines. Its utility as a follow-up diagnostic when genetic or sweat chloride tests are inconclusive further enhances its portfolio relevance for CF and related ion channelopathies.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables direct interrogation of CFTR and ENaC activity in human airway tissue.
- Supports functional target validation for ion channel modulators in CF and related disorders.
- Provides mechanistic de-risking by linking molecular intervention to physiological effect.
- Facilitates predictive confidence in candidate selection and triage.
Screening & Assay Development
- Establishes a validated, quantitative assay for measuring ion transport in airway epithelium.
- Supports assay standardization and reproducibility across research sites.
- Generates robust, quantitative outputs for compound evaluation in proof-of-concept studies.
- Enables screening readiness for agents targeting CFTR and ENaC function.
Translational & Preclinical Research
- Aligns with disease-relevant endpoints for CF and other epithelial ion transport disorders.
- Provides translational continuity from preclinical models to human tissue assessment.
- Supports risk-adjusted advancement decisions based on functional biomarker readouts.
- Offers predictive de-risking for clinical trial design and patient stratification.
Pipeline & Workflow Integration
NPD measurement bridges early discovery, lead identification, and translational research by providing a functional biomarker for ion channel activity in human tissue.
- Discovery Biology: Enables hypothesis testing and pathway clarification for CFTR and ENaC modulation.
- Screening: Delivers reproducible, quantitative assay outputs for compound prioritization.
- Analytics: Provides voltage-based measurements to compare intervention effects across conditions.
- Translational Research: Connects preclinical findings to human disease-relevant endpoints.
- Enterprise Reuse: Functions as a reusable platform for evaluating diverse ion channel-targeted therapies.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in target validation.
- Operational Value: Promotes assay standardization, reproducibility, and cross-site comparability.
- Strategic Value: Informs go/no-go decisions and enhances capital efficiency in CF and ion channel portfolios.
- Portfolio Impact: Supports risk-adjusted prioritization and advancement of candidate therapies.
Implementation Considerations
- Requires specialized operator training and technical expertise for reliable data acquisition.
- Demands dedicated electrophysiological instrumentation and analytical infrastructure.
- Necessitates cross-team standardization to minimize inter- and intra-subject variability.
- May require adaptation for use in pediatric or uncooperative subjects due to variability concerns.
- Interpretation benefits from validated algorithms to enhance consistency and decision-making.
Biopharma FAQs
Chapters in this video
0:04
Title
1:01
Materials Setup
2:19
Measurement Electrode Placement
4:35
Basal Potential Difference (PD) Measurement
6:02
Nasal Membrane Transepithelial Potential Difference (NPD) Tracing Sequential Perfusions
7:42
Results: Representative CF and Healthy Subject Tracings
8:57
Conclusion
